Dr Andrew Davies, Southampton, UK, Professor John Radford, The University of Manchester, UK, Professor Peter Johnson, Southampton University, UK, Dr Karl Peggs, University College Hospital, London, Professor Stephen… read more.
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
by Christine Clark: The National Cancer Information Network (NCIN) was established to drive change and improve cancer outcomes. Analyses show large variations in practices and outcomes some of… read more.
Dr Graham Collins from the Oxford Cancer and Haematology Centre, Oxford, UK.
by Bruce Sylvester: Researchers from a phase 3, randomized trial of brentuximab vedotin report that adults with hard-to-treat Hodgkin lymphoma treated with brentuximab vedotin immediately after stem cell… read more.
by Thomas R. Collins: Treating patients with T-cell lymphomas is fraught with challenges, requiring new approaches and sharper diagnosis, said Timothy Illidge, MD, PhD, Professor of Targeted Therapy… read more.
by Thomas R. Collins: The use of chimeric antigen receptor T-cells — in which a patient’s own T cells are modified to fight cancer cells — is showing good results… read more.
by Thomas R. Collins: Pursuit of useful risk biomarkers in HL still a work-in-progress. The quest for biomarkers in classic Hodgkin lymphoma, to determine which patients are at a… read more.
Engagement of patients and understanding of early death in this group by Denys Wheatley. (1) When and why do teenage and young adult oncology patients die early in… read more.
Ger Walpole, CNS (Clinical Nurse Specialist), H.Dip Oncology Nursing, BNS(Hons), Sligo Regional Hospital, Sligo. Dr Andrew Hodgson, MB, BS, BSc (Hons), FRCPI, FFPath, FRCPath. Written by Karen Mas-Mollinedo… read more.
by Denys Wheatley: ESMO Madrid September 2014. Session Monday 29 September 11.00. PET imaging – Potential, pitfalls, and future directions. Two talks on Hodgkin (HL) and non-Hodgkin lymphoma… read more.
by Denys Wheatley: ESMO Madrid September 2014: Session on Sunday 28 September (poster). Dr Moccia and his group in Bellinzona (Switzerland) report on the marked improvement over 30… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
